Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

ILLUMINA, INC.

(ILMN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina: 3Q Earnings Snapshot

10/29/2020 | 03:58pm EST

SAN DIEGO (AP) _ Illumina Inc. (ILMN) on Thursday reported third-quarter earnings of $179 million.

The San Diego-based company said it had profit of $1.21 per share. Earnings, adjusted for non-recurring gains, came to $1.02 per share.

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 77 cents per share.

The genetic testing tools company posted revenue of $794 million in the period, also surpassing Street forecasts. Five analysts surveyed by Zacks expected $720.8 million.

Illumina shares have dropped 5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $314.90, a climb of slightly more than 4% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ILMN at https://www.zacks.com/ap/ILMN

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about ILLUMINA, INC.
01/22ILLUMINA : Insider Sales at Illumina (ILMN) are Significant and Extend the Selli..
MT
01/21INSIDER TRENDS : Insider 90-Day Selling Trend Extended at Illumina
MT
01/21INSIDER TRENDS : Illumina Insider Extends 90-Day Selling Trend
MT
01/20ILLUMINA : Gets Favorable Infringement Ruling From Patents Court
MT
01/20ILLUMINA : Wins Patent Infringement Suit against BGI in the UK
BU
01/14Qiagen warns against using standard tests to track coronavirus variants
RE
01/12ILLUMINA, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
01/11ILLUMINA : New Bioinformatics Solution Powers Multi-Omics Discovery at Massive S..
BU
01/11ILLUMINA : Announces New and Expanded Oncology Partnerships with Bristol Myers S..
BU
01/11Grail in Minimum Residual Disease Collaborations With Amgen, AstraZeneca, Bri..
DJ
More news
Financials (USD)
Sales 2020 3 180 M - -
Net income 2020 543 M - -
Net cash 2020 2 230 M - -
P/E ratio 2020 110x
Yield 2020 -
Capitalization 59 313 M 59 313 M -
EV / Sales 2020 18,0x
EV / Sales 2021 14,7x
Nbr of Employees 7 700
Free-Float 75,1%
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 331,88 $
Last Close Price 406,25 $
Spread / Highest target 10,8%
Spread / Average Target -18,3%
Spread / Lowest Target -38,5%
EPS Revisions
Managers and Directors
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Phillip G. Febbo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.9.80%59 313
THERMO FISHER SCIENTIFIC10.00%203 954
DANAHER CORPORATION7.16%169 098
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.12.25%89 689
INTUITIVE SURGICAL, INC.-9.05%87 471
SIEMENS HEALTHINEERS AG6.55%58 301